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Background and aims: In previous phase III studies, the PCSK9 monoclonal antibody alirocumab was
administered at doses of 75 or 150 mg every 2 weeks (Q2W). CHOICE I (NCT01926782) evaluated 300 mg
every 4 weeks (Q4W) in patients on either maximally tolerated statin or no statin, both ± other lipid-
lowering therapies.
Methods: CHOICE I included patients with hypercholesterolemia at moderate-to-very-high cardiovas-
cular risk. Patients were randomized to alirocumab 300 mg Q4W, 75 mg Q2W (calibrator arm), or pla-
cebo for 48 weeks, with dose adjustment for either alirocumab arm to 150 mg Q2W at Week (W) 12 if at
W8 LDL-C levels were >70/100 mg/dL (1.8/2.6 mmol/L) depending on cardiovascular risk or LDL-C
reduction was <30% from baseline. Co-primary endpoints were percent LDL-C change from baseline to
W24, and to time-averaged LDL-C over W21e24.
Results: Approximately two-thirds of randomized patients were receiving statins. At W12, 14.7% (no
statin) and 19.3% (statin) of patients receiving alirocumab 300 mg Q4W required dose adjustment. At
W24, signiﬁcant LDL-C reductions from baseline were observed with alirocumab 300 mg Q4W: mean
differences were 52.7% (no statin; placebo: e0.3%) and 58.8% (statin; placebo: e0.1%). Average LDL-C
reductions from baseline to W21e24 were also signiﬁcantly greater with alirocumab 300 mg Q4W vs.
placebo in patients not receiving (56.9% vs. e1.6%) and receiving statin (65.8% vs. e0.8%). Treatment-
emergent adverse event rates ranged from 61.1 to 75.0% (placebo) and 71.5 to 78.1% (alirocumab 300 mg
Q4W).
Conclusions: Alirocumab 300 mg Q4W is a viable additional treatment option in patients requiring LDL-
C-lowering.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Alirocumab is a fully human monoclonal antibody to proprotein
convertase subtilisin/kexin type 9 (PCSK9), a key regulator of the
low-density lipoprotein (LDL) receptor and ultimately LDLoth).
Ireland Ltd. This is an open accesscholesterol (LDL-C) levels. In prior phase III studies, using a dosing
regimen of 75 mg every 2 weeks (Q2W) (with possible dose
adjustment to 150 mg Q2W) added to background statin with or
without other lipid-lowering therapies (LLTs) or as monotherapy,
alirocumab reduced LDL-C levels by 44e54% [1e3]. Alirocumab
150 mg Q2W reduced LDL-C levels by 61% on background
statin ± other LLTs [4]. Beneﬁcial effects were also seen on other
atherogenic lipid parameters, including non-high-densityarticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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lipoprotein (a) [Lp(a)] [1e4]. For some patients a dosing regimen of
alirocumab every 4 weeks (Q4W) might be a preferred option.
The magnitude and duration of LDL-C reductions with alir-
ocumab are related to dose and its rate of elimination following
administration [5e7]. Alirocumab elimination occurs through
nonspeciﬁc mechanisms as well as speciﬁc mechanisms related to
its binding to PCSK9 in a process known as target-mediated clear-
ance [8]. Statins are known to increase PCSK9 levels [9,10] and,
when co-administered with alirocumab, appear to reduce alir-
ocumab's duration of effect via enhanced target-mediated clear-
ance in the setting of Q4W dosing [8]. In contrast, fenoﬁbrate and
ezetimibe were associated with only limited impact on alirocumab
duration of effect [11].
In a phase II study of patients with heterozygous familial hy-
percholesterolemia receiving stable statin, LDL-C reductions on
alirocumabwere not fully maintained over the dosing interval in all
statin-treated patients. Although alirocumab 150 mg Q4W reduced
LDL-C levels from baseline by 61% at Week 10 (2 weeks post-
alirocumab dose), the mean reduction at Week 12 was 28.9% (4
weeks post-alirocumab dose) [5], suggesting that this dosing
strategy may not be appropriate for those receiving concomitant
statin. The effectiveness of this dose of alirocumab (150mg Q4W) in
patients with hypercholesterolemia who are not receiving statin
therapy has been investigated further in the ODYSSEY CHOICE II
study [12].
Using a higher dose of 300 mg Q4W (vs.150 mg Q4W), a greater
reduction of 42.5% was maintained at Week 12 in patients with
heterozygous familial hypercholesterolemia receiving statin ther-
apy, suggesting that this dose could be an option for some patients
both with and without concomitant statin [5]. Furthermore, in a
separate phase II study including patients with baseline LDL-C
levels of 100 mg/dL (2.6 mmol/L) receiving stable atorvastatin
10e40mg daily, LDL-C reductions of 43.2% with alirocumab 200mg
Q4W and 47.7% with alirocumab 300 mg Q4W were achieved [6].
The objective of the phase III ODYSSEY CHOICE I study
(NCT01926782) was to determine the efﬁcacy, long-term safety,
and tolerability of a potential starting dose regimen of alirocumab
300 mg Q4W (with dose adjustment depending on individual pa-
tient response) either as add-on to maximally tolerated doses of
statin (with or without other LLTs) or when used without statin.
This study used alirocumab 75 mg Q2W as a calibrator arm.
2. Materials and methods
ODYSSEY CHOICE I was a randomized, double-blind, placebo-
controlled, phase 3 multinational study which enrolled 803 pa-
tients from 105 study sites from the USA (n ¼ 63), Canada (n ¼ 7),
Hungary (n ¼ 6), the United Kingdom (n ¼ 10), Bulgaria (n ¼ 5),
Israel (n ¼ 5), Slovakia (n ¼ 6), and Norway (n ¼ 3). The study was
initiated on October 24, 2013 (ﬁrst patient screened), with the ﬁrst
patient randomized on November 4, 2013 and the last patient
randomized on May 12, 2014. The study was conducted in accor-
dance with the ethical principles in the Declaration of Helsinki and
applicable amendments, and the International Conference on
Harmonization for Good Clinical Practice guidelines. The protocol
was approved by the relevant institutional review board or inde-
pendent ethics committee, and all participating patients provided
written informed consent.
2.1. Patients
The study included adult patients (aged >18 years) who did not
have adequately controlled hypercholesterolemia, with (a)
moderate-to-very-high cardiovascular disease (CVD) risk andreceiving the maximally tolerated dose of statin, (b) moderate-to-
very-high CVD risk and with statin-associated muscle symptoms
(deﬁned in protocol as muscle-related statin intolerance), or (c)
moderate CVD risk and not receiving statin. Enrollment was strat-
iﬁed so that approximately two-thirds of the randomized patients
were receiving concomitant statin therapy, with enrollment of
patients receiving statins and with moderate CVD risk capped at
25% of the statin subgroup.
Patients receiving concomitant statin were to receive stable
daily doses (for at least 4 weeks) of rosuvastatin 20e40 mg, ator-
vastatin 40e80 mg, or simvastatin 80 mg (which must have been at
a stable dose for 1 year), or maximally tolerated dose of one of
these three statins. Background treatment with LLTs other than
statins was allowed for all patients, provided they had been on a
stable dose for at least 4 weeks (6 weeks for fenoﬁbrate) prior to
study entry, excluding statins (other than atorvastatin, rosuvasta-
tin, or simvastatin), ﬁbrates other than fenoﬁbrate, and red yeast
rice products. A list of exclusion criteria is given in Supplementary
Table 1. Patients were required to follow a stable diet equivalent to
the National Cholesterol Education Program Adult Treatment Panel
III (NCEP ATP III) Therapeutic Lifestyle Changes diet from screening
to end of study [13].
Baseline LDL-C level was required to be70mg/dL (1.8 mmol/L)
if the patient was considered at very high CVD risk or 100 mg/dL
(2.6 mmol/L) if the patient was considered at high ormoderate CVD
risk, with these levels based on the NCEPATP III guidelines available
when the study was initiated [13]. In addition, the population of
patients who were not on statin therapy was restricted to patients
whowere at moderate CVD risk with LDL-C100mg/dL (1.8 mmol/
L) and <160 mg/dL (4.1 mmol/L) at screening. Patients considered
statin intolerant were required to have LDL-C 70/100 mg/dL (1.8/
2.6 mmol/L; depending on cardiovascular risk) and <160 mg/dL
(4.1 mmol/L) if not on any non-statin LLT; however, there was no
upper LDL-C limit for patients who were statin intolerant and
receiving clinically appropriate LLT, as they were already on best
standard of care.
Very-high, high, and moderate CVD risk were deﬁned according
to previously deﬁned methods [14]. Very-high CVD risk was
deﬁned as documented coronary heart disease (CHD) or CHD risk
equivalents (ischemic stroke, transient ischemic attack, carotid ar-
tery occlusion >50% without symptoms, carotid endarterectomy or
carotid artery stent procedure, peripheral arterial disease, abdom-
inal aortic aneurysm, renal artery stenosis, renal artery stent pro-
cedure, or type 1 or type 2 diabetes mellitus with target organ
damage). High CVD risk was deﬁned as no CHD/CVD but with a
Systematic Coronary Risk Evaluation (SCORE) [15] 10-year fatal CVD
risk 5%, moderate chronic kidney disease, type 1 or type 2 dia-
betes mellitus without target organ damage, or heterozygous fa-
milial hypercholesterolemia (by genetic or clinical criteria).
Moderate CVD risk was deﬁned as a SCORE of between1 and <5%.
Statin-associated muscle symptoms were deﬁned as per a previous
study in the protocol as statin intolerance, and included the
inability to tolerate at least two statins: one statin at the lowest
daily starting dose and another statin at any dose, due to skeletal
muscle-related symptoms [14].
2.2. Study procedures
The study comprised a 3-week screening period, followed by 48
weeks of double-blind treatment and 8 weeks of follow-up (off-
treatment). Patients were randomized using a permuted block
design in a 4:2:1 ratio to receive alirocumab 300 mg Q4W, placebo,
or alirocumab 75 mg Q2W (Fig. 1). Each treatment was adminis-
tered subcutaneously as 2  1 mL injections (placebo or alir-
ocumab) by pre-ﬁlled syringe. To maintain the blind, all patients
Fig. 1. CHOICE I study design. a. Dosing regimen changed in both alirocumab groups at Week 12 if LDL-C at Week 8 70 mg/dL (1.8 mmol/L) or 100 mg/dL (2.6 mmol/L),
depending on cardiovascular risk, or if LDL-C reductionwas <30% from baseline at Week 8. b. The blind was maintained in all patients, including those receiving dose adjustment, by
giving the study treatment as two 1 mL subcutaneous injections Q2W. Placebo group: 2 injections of placebo Q2W; alirocumab 75Q2Wgroup: 1 injection of 75 mg alirocumab and 1
injection of placebo Q2W; alirocumab 300Q4W group: 2 injections Q2W, consisting of 2 injections of 150 mg alirocumab Q4W alternating with 2 injections of placebo Q4W. LDL-C,
low-density lipoprotein cholesterol; LLT, lipid-lowering therapy; R, randomization; Q2W, every 2 weeks; Q4W, every 4 weeks.
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was trained to self-inject/inject using placebo. Randomization was
stratiﬁed according to statin therapy vs. no statin therapy, and
moderate vs. high and very-high CVD risk within the population
receiving concomitant statin.
Alirocumab patients (in the alirocumab 300 mg Q4Wand 75mg
Q2W treatment groups) not achieving target LDL-C levels of
<70 mg/dL (1.8 mmol/L) or <100 mg/dL (2.6 mmol/L) (depending
on CVD risk) at Week 8, or if their LDL-C level was reduced by30%
from baseline at Week 8, had their alirocumab dosing regimen
changed to 150 mg Q2W at Week 12 in a blinded fashion.
On-site visits took place during the double-blind period at
Weeks 0 (baseline, i.e., randomization visit), 2, 4, 6, 8, 10, 12, 16, 20,
21, 22, 23, 24, 36, and 48.2.3. Endpoints
The co-primary endpoints were the percent change in calcu-
lated LDL-C from baseline to Week 24, and the percent change in
calculated LDL-C from baseline to the average over Weeks 21e24
(alirocumab 300 mg Q4W vs. placebo, according to randomization)
using all LDL-C values regardless of adherence to treatment (intent-
to-treat [ITT] approach). This was analyzed separately for the study
populations receiving concomitant statin and those not receiving
statin. The weekly assessment between Weeks 21e24 evaluated
the efﬁcacy of alirocumab between the dosing intervals.
The percent change in calculated LDL-C from baseline to Week
24 was also assessed using all LDL-C values during the efﬁcacy
treatment period (on-treatment approach) (key secondary
endpoint). Other key secondary endpoints included the percent
change in calculated LDL-C from baseline to Week 12, the propor-
tion of patients achieving LDL-C targets of <70 mg/dL (1.8 mmol/L;
very high cardiovascular risk) or <100 mg/dL (2.6 mmol/L) at Week
24 (moderate or high cardiovascular risk), and the percent change
in Apo B, non-HDL-C, total cholesterol, Lp(a), fasting triglycerides,
HDL-C, and Apo A1 from baseline to Weeks 12 and 24. Other sec-
ondary endpoints included the percent change in calculated LDL-C
from baseline toWeek 48, and the proportion of patients achieving
LDL-C targets at Weeks 12 and 48.
Safety was assessed primarily from the reporting of treatment-
emergent adverse events (TEAEs), deﬁned as those occurring be-
tween the date of ﬁrst study drug injection to the date of the last
study drug injection plus 70 days, and by laboratory parameters,vital signs, and electrocardiogram.
Safety events of interest, requiring completion of a special
electronic case report form (e-CRF), included general allergic re-
actions, cardiovascular events, injection-site reactions, hemolytic
anemia, neurologic events, ophthalmologic events, and increased
alanine aminotransferase levels. Neurocognitive events, an addi-
tional safety event of interest, did not require completion of an e-
CRF and were identiﬁed by custom Medical Dictionary of Regula-
tory Activities queries. For further details on safety events of in-
terest and preferred terms for the adverse event categories, see the
Supplementary material.
To assess development of anti-drug antibodies (ADAs) to alir-
ocumab, blood samples were collected before study drug admin-
istration at baseline and scheduled clinic visit at Weeks 12, 24, 36,
48, and at the end of study visit. These were analyzed using a
validated assay by Regeneron Pharmaceuticals, Inc. (Tarrytown,
NY).
Free PCSK9 levels were determined using a speciﬁc validated
enzyme-linked immunosorbent assay (Regeneron Pharmaceuticals
Inc., Tarrytown, NY). The lower limits of detectionwere 31.2 ng/mL.
Free PCSK9 levels were measured up to Week 24.2.4. Statistical analysis
A total sample size of 39 patients receiving concomitant statin
(26 patients on alirocumab 300 mg Q4W and 13 patients on pla-
cebo) or 30 patients not receiving statin (20 alirocumab and 10
placebo) was determined to have 95% power to detect a between
treatment-group difference of 40% (no statin population) and 35%
(statin population) in the primary endpoint using a two-sided
signiﬁcance level of 0.025 and assuming a common standard de-
viation of 25%. However, the total sample size was increased to 400
patients on alirocumab 300 mg Q4W and 200 patients on placebo
to provide additional safety data for the 300 mg Q4W dose.
The primary efﬁcacy analysis included all randomized patients
with an LDL-Cmeasurement available at baseline and at least one of
the post-randomization time points between Weeks 4 and 24,
regardless of treatment adherence (ITT population), and was
analyzed using a mixed-effects model with repeated measures,
with parameters to account for missing data as previously reported
[14,16e18].
Key secondary lipid endpoints were analyzed in a predeﬁned
order using a hierarchical inferential approach to control type I
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except Lp(a), which was analyzed using a multiple imputation
approach then robust regression, and triglycerides and LDL-C goal
achievement, which were analyzed using logistic regression.
The safety analysis included all randomized patients who
received at least one dose or part of a dose of study drug. Safety data
were analyzed by descriptive statistics.
3. Results
3.1. Patients
A total of 1491 patients were screened, of whom 803 were
randomized according to their statin treatment status
(Supplementary Fig. 1). For the no concomitant statin cohort, 146
patients were randomized to alirocumab 300 mg Q4W (with
possible dose adjustment to 150 mg Q2W, to be further referred to
as “300Q4W”), 73 to receive placebo, and 37 to alirocumab 75 mg
Q2W (with possible dose adjustment to 150 mg Q2W, to be further
referred to as “75Q2W”). For the concomitant statin cohort, 312
were randomized to alirocumab 300Q4W, 157 to receive placebo,
and 78 to alirocumab 75Q2W. The ITT population included 792
patients overall, and the safety population included 802.
A total of 187 (73.0%) patients in the no statin population (alir-
ocumab 300Q4W, 71.9%; placebo, 72.6%; alirocumab 75Q2W,
78.4%) and 466 (85.2%) patients in the concomitant statin popula-
tion (alirocumab 300Q4W, 87.2%; placebo, 82.2%; alirocumab
75Q2W, 83.3%) completed the study treatment period. Reasons for
study discontinuation are given in Supplementary Table 2. Over the
48-week treatment period, 8.2% and 6.2% of patients discontinued
study treatment due to TEAEs in the no statin and the concomitant
statin populations, respectively.
Baseline characteristics and lipid parameters were generally
similar across the treatment arms of both the no statin and statin
cohorts, with some discrepancies between groups not anticipated
to have a clinically signiﬁcant impact on the overall study results
(Table 1). Statin-associated muscle symptoms were the reason that
42.2% (n ¼ 108/256) of the patients were not receiving statin
therapy. Other reasons are given in Supplementary Table 3. At
randomization, 0.4% of patients in the no statin groups were
receiving statin, due to randomization error, and 43.8% were on
other LLT, whereas 99.8% of patients in the concomitant statin
cohort were on statins and 36.4% of patients were on other LLT. In
general, the percent of patients receiving background LLT (other
than statin) was broadly comparable across patients (Table 1).
Comparing the study cohorts, patients not on statin had a higher
mean baseline LDL-C level (142.1 mg/dL [3.7 mmol/L]) vs. those on
concomitant statin (112.7 mg/dL [2.9 mmol/L]).
3.2. Efﬁcacy endpoints
The least-squares mean (standard error) change from baseline
to Week 24 in LDL-C level was 52.7% (1.9) with alirocumab
300Q4W (vs. e0.3% [2.7%] with placebo) in patients not receiving
statin and 58.8% (1.6%) (vs. e0.1% [2.3%] with placebo) in patients
receiving concomitant statin (both p < 0.0001, Supplementary
Table 4). The average LDL-C reduction from baseline to averaged
Weeks 21e24 was also signiﬁcantly greater for alirocumab
300Q4W vs. placebo in both patient populations (56.9% [1.8%]
[alirocumab 300Q4W] and 1.6% [2.6%] [placebo] in patients not
receiving statin; e65.8% [1.4%] [alirocumab 300Q4W] and 0.8%
[2.0%] [placebo] in patients receiving concomitant statin; and both
groups: p < 0.0001; Supplementary Table 5). Signiﬁcant LDL-C re-
ductions were maintained with alirocumab 300Q4W from baseline
to Week 48 vs. placebo in patients not on statin (45.7% [2.1%] vs.e1.0% [3.0%]) and those on statin (51.9% [1.8%] vs. þ6.2% [2.5%];
both: p < 0.0001) (Supplementary Table 5).
LDL-C reductions with alirocumab 300Q4Wwere observed from
Week 4 and maintained through the treatment period. Overall,
reductions in LDL-C in the alirocumab 300Q4W group were of a
similar magnitude to those observed in the alirocumab 75Q2W
group (Fig. 2 and Supplementary Table 5). With alirocumab
300Q4W, LDL-C reductions were more sustained between in-
jections in the cohort not on statin vs. the cohort receiving
concomitant statin (Fig. 2). Weekly analyses betweenWeeks 21 and
24 (i.e., after possible dosing regimen adjustment) found generally
consistent alirocumab efﬁcacy over this time, regardless of statin
use (Fig. 2 and Supplementary Table 5).
Percent reductions in LDL-C at Week 12 (i.e., before dosing
regimen adjustment) for all groups are shown in Supplementary
Table 5. At Week 12, in the alirocumab 300Q4W group the dosing
regimen was adjusted to alirocumab 150 mg Q2W in 14.7% and
19.3% of patients in the no statin and concomitant statin pop-
ulations, respectively (Fig. 3). The adjusted dosing regimen was
associated with reduced variability in LDL-C levels from week to
week (as observed between Weeks 21 and 24), in particular for
patients on concomitant statin (Figs. 2 and 3).
AtWeek 24, most patients receiving alirocumab 300Q4W (78.9%
of patients not receiving statin; 85.2% of patients on concomitant
statin) achieved LDL-C levels of <70 mg/dL (1.8 mmol/L) or
<100 mg/dL (2.6 mmol/L), depending on their cardiovascular risk
(both patient groups p < 0.0001 vs. placebo; Supplementary
Table 5). At Week 48, 66.2% of patients not receiving statin and
78.2% of those on statin achieved their pre-deﬁned goals in the
alirocumab 300Q4W groups (Supplementary Table 5).
Alirocumab 300Q4W signiﬁcantly improved all key secondary
efﬁcacy lipid parameters vs. placebo, regardless of statin use (all
p  0.005, with the exception of Apo A1 at Week 24 in patients on
concomitant statin [p¼ 0.0306]; Supplementary Table 4), including
Lp(a) (21.3% [no statin group] and 19.3% [statin group];
p < 0.0001 vs. placebo). At Week 48, alirocumab resulted in
generally consistent improvements of the secondary efﬁcacy lipid
parameters (Supplementary Table 6).
Across various subgroups deﬁned by demographic and baseline
characteristics, a consistent reduction in LDL-C was observed at
Week 24 (Supplementary Fig. 2) and averaged Weeks 21e24
(Supplementary Fig. 3). Regardless of LDL-C baseline levels, pa-
tients randomized to the alirocumab 300Q4Wgroup demonstrated
reductions in LDL-C of 47.7e64.2% at Week 24 (Supplementary
Fig. 2E and F) and 52.7e69.5% at averaged Weeks 21e24
(Supplementary Fig. 3E and F); however, patients on statin with
baseline LDL-C of <100 mg/dL (2.6 mmol/L) tended to show a
greater difference (Week 24: e60.4%; averaged Weeks 21e24:
e69.5%) vs. placebo (þ8.6% and þ9.6%, respectively) than those
with higher LDL-C levels (Supplementary Figs. 2F and 3F).
3.3. Free PCSK9
In general, predictable dynamics were apparent between PCSK9
and LDL-C levels, with reductions in free PCSK9 consistent with the
observed reductions in LDL-C. Patients who were not on statin
tended to have lower free PCSK9 levels at baseline and achieved
extremely low free PCSK9 levels between Weeks 21e24
(5.0e24.8 ng/mL) (Fig. 2). In the statin group, free PCSK9 levels
tended to be higher at baseline than in those not receiving statin
and decreased to very low levels between Weeks 21e23
(10.6e26.3 ng/mL) before rising to 88.1 ng/mL towards the end of
the dosing period at Week 24 (Fig. 2). Those patients who required
dose adjustment at Week 12 tended to have higher LDL-C and
higher free PCSK9 levels at both baseline and Week 12 (Fig. 3).
Table 1
Baseline characteristics (randomized population).
Patients not receiving statin Patients receiving statin
Alirocumab Placebo (n ¼ 73) Alirocumab Placebo
(n ¼ 157)
75Q2W (n¼ 37) 300Q4W
(n ¼ 146)
75Q2W (n¼ 78) 300Q4W
(n ¼ 312)
Baseline demographics
Age, mean (SD) 59.3 (11.3) 59.2 (10.8) 59.4 (10.2) 60.7 (9.1) 61.6 (10.0) 61.6 (9.7)
Male, n (%) 14 (37.8) 66 (45.2) 40 (54.8) 51 (65.4) 190 (60.9) 101 (64.3)
Race, White, n (%) 32 (86.5) 123 (84.2) 62 (84.9) 68 (87.2) 279 (89.4) 137 (87.3)
Race, Black or African-American, n (%) 4 (10.8) 17 (11.6) 9 (12.3) 8 (10.3) 29 (9.3) 18 (11.5)
Ethnicity, Hispanic/Latino, n (%) 3 (8.1) 8 (5.5) 4 (5.5) 1 (1.3) 5 (1.6) 5 (3.2)
BMI, kg/m2, mean (SD) 29.7 (5.0) 30.9 (5.7) 32.3 (6.7) 30.1 (4.9) 31.4 (6.2) 30.9 (6.2)
Diagnosis of HeFH, n (%) 0 2 (1.4) 1 (1.4) 6 (7.7) 26 (8.3) 12 (7.6)
By genotyping 0 0 0 2 (33.3) 13 (50.0) 2 (16.7)
By WHO/Simon Broome criteria 0 2 (100) 0 4 (66.7) 13 (50.0) 10 (83.3)
Diabetes mellitus (type 2), n (%) 4 (10.8) 28 (19.2) 17 (23.3) 22 (28.2) 96 (30.8) 50 (31.8)
Cardiovascular risk, n (%)
Very high 7 (18.9) 33 (22.6) 20 (27.4) 55 (70.5) 204 (65.4) 102 (65.0)
High 8 (21.6) 22 (15.1) 15 (20.5) 12 (15.4) 66 (21.2) 31 (19.7)
Moderate 22 (59.5) 91 (62.3) 38 (52.1) 11 (14.1) 42 (13.5) 24 (15.3)
Lipid treatment
Patients on atorvastatin, rosuvastatin, or simvastatin at
randomization, n (%)
0 2 (1.4)a 0 78 (100) 310 (99.4) 157 (100)
Any LLT other than statins, n (%)b 12 (32.4) 67 (45.9) 33 (45.2) 21 (26.9) 125 (40.1) 53 (33.8)
Any LLT other than nutraceuticals, n (%) 5 (13.5) 41 (28.1) 20 (27.4) 16 (20.5) 86 (27.6) 38 (24.2)
Ezetimibe, n (%) 3 (8.1) 10 (6.8) 11 (15.1) 9 (11.5) 43 (13.8) 22 (14.0)
Nutraceuticals, n (%) 8 (21.6) 47 (32.2) 19 (26.0) 12 (15.4) 62 (19.9) 24 (15.3)
Baseline lipid parameters, mg/dL, mmol/L or g/L
LDL-C (calculated), mean (SD) 148.4 (36.8)
3.842 (0.953)
146.1 (33.5)
3.785 (0.868)
131.0 (30.4)
3.392 (0.787)
114.9 (36.0)
2.977 (0.933)
112.4 (32.8)
2.912 (0.850)
112.1 (37.3)
2.903 (0.965)
LDL-C (measured), mean (SD) 154.7 (39.2)
4.006 (1.016)
149.7 (34.1)
3.877 (0.884)
134.1 (28.9)
3.473 (0.749)
118.0 (35.1)
3.057 (0.910)
115.4 (30.6)
2.989 (0.793)
115.8 (37.2)
2.998 (0.962)
Non-HDL-C, mean (SD) 175.7 (40.8)
4.550 (1.056)
176.5 (38.0)
4.572 (0.983)
162.8 (34.7)
4.218 (0.899)
146.4 (42.3)
3.791 (1.095)
141.3 (35.4)
3.658 (0.916)
140.0 (41.9)
3.626 (1.085)
Total cholesterol, mean (SD) 233.9 (41.9)
6.059 (1.085)
228.9 (38.7)
5.930 (1.002)
212.6 (36.2)
5.507 (0.936)
195.3 (43.6)
5.058 (1.130)
191.4 (37.8)
4.956 (0.980)
190.5 (44.4)
4.935 (1.150)
Apo B, mean (SD) 115.9 (24.7)
1.159 (0.247)
117.3 (22.7)
1.173 (0.227)
109.8 (21.6)
1.098 (0.216)
99.6 (25.0)
0.996 (0.250)
96.6 (21.3)
0.966 (0.213)
96.0 (24.3)
0.960 (0.243)
Lp(a), median (Q1:Q3) 13.0 (6.0:45.0)
0.130
(0.060:0.450)
15.0 (7.0:42.0)
0.150
(0.070:0.420)
12.5 (6.0:39.0)
0.125
(0.060:0.390)
28.0 (9.5:58.0)
0.280
(0.095:0.580)
27.0 (7.0:65.0)
0.270
(0.070:0.650)
25.5 (7.0:73.0)
0.255
(0.070:0.730)
HDL-C, mean (SD) 58.2 (15.0)
1.509 (0.389)
52.4 (16.4)
1.357 (0.426)
49.8 (15.4)
1.290 (0.399)
48.9 (14.1)
1.267 (0.365)
50.1 (14.8)
1.298 (0.383)
50.5 (15.7)
1.309 (0.407)
Fasting TGs, median (Q1:Q3) 120.0
(86.0:172.0)
1.356
(0.972:1.944)
136.5
(93.0:190.0)
1.542
(1.051:2.147)
139.0
(101.0:201.0)
1.571
(1.141:2.271)
132.0
(99.0:171.0)
1.492
(1.119:1.932)
128.0
(95.0:173.0)
1.446
(1.074:1.955)
125.0
(93.0:176.0)
1.413
(1.051:1.989)
Apo A1, mean (SD) 166.4 (26.7)
1.664 (0.267)
157.1 (30.4)
1.571 (0.304)
153.1 (29.3)
1.531 (0.293)
149.3 (26.5)
1.493 (0.265)
149.0 (27.4)
1.490 (0.274)
147.6 (30.6)
1.476 (0.306)
75Q2W, 75 mg every 2 weeks (with possible dose adjustment to 150 mg every 2 weeks); 300Q4W, 300 mg every 4 weeks (with possible dose adjustment to 150 mg every 2
weeks); Apo, apolipoprotein; BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; HeFH, heterozygous familial hypercholesterolemia; LDL-C, low-density
lipoprotein cholesterol; LLT, lipid-lowering therapy; Lp(a), lipoprotein (a); SD, standard deviation; TGs, triglycerides; WHO, World Health Organization.
a Patients received statin due to randomization error.
b In combination with statins or not. Patients could be receiving more than one category of LLT.
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The overall frequency of TEAEs ranged from 79.2 to 83.6% in the
alirocumab 300Q4Wgroup and 73.2 to 77.8% in the placebo groups,
depending on statin status (Table 2). There were three deaths. The
frequency of treatment-emergent serious adverse events was
generally consistent across each cohort (Table 2). Among all treat-
ment groups, 5.1e9.6% of patients prematurely discontinued study
treatment because of one or more TEAE (Table 2). The frequency of
TEAEs occurring within the system organ class “musculoskeletal
and connective tissue disorders” was similar between patients
treated with alirocumab 300Q4W and placebo, irrespective of
background statin use (Supplementary Table 7). Of these patients, 3
(0.7%) discontinued study treatment due to muscle pain. A higher
proportion of patients experienced injection-site reactions in thealirocumab 300Q4Wgroup compared with placebo and alirocumab
75Q2Wgroups. Most of these events (92.3%) were classiﬁed as mild
in intensity, and most patients (97.1%) experiencing these
continued to receive study treatment (Supplementary Table 7).
Overall, 12 and nine patients experienced cardiovascular and neu-
rocognitive events, respectively, during the study (Table 2).
LDL-C levels <25 mg/dL (0.6 mmol/L) on at least two consecu-
tive occasions (measurements 21 days apart) were observed in
118 alirocumab-treated patients (20.6%; 300Q4W and 75Q2W;
Supplementary Table 8). The overall adverse event proﬁle appeared
similar to those patients without such low LDL-C levels.3.5. Immunogenicity
Overall, ADA positivity was not associated with decreased
Fig. 2. Mean (SE) calculated LDL-C levels (A and C) and free PCSK9 levels (B and D) over time in patients not receiving concomitant statin therapy (A and B) and patients
receiving concomitant statin therapy (C and D) (ITT population) e time proﬁle of patients. a. At Week 12, 14.7% and 21.2% of patients in the no statin population and 19.3% and
19.7% of those in the statin population received dose adjustment to 150 mg Q2W, based on Week 8 LDL-C levels, in the alirocumab 300 mg Q4W and 75 mg Q2W groups,
respectively. b. DW24 deﬁned as % change in calculated LDL-C from baseline to Week 24 vs. placebo in the ITT population. c. Absolute LDL-C value. d. DW21e24 deﬁned as % change
in calculated LDL-C from baseline to averaged values from Weeks 21e24 vs. placebo in the ITT population. 75Q2W, 75 mg every 2 weeks (with possible dose adjustment to 150 mg
every 2 weeks); 300Q4W, 300 mg every 4 weeks (with possible dose adjustment to 150 mg every 2 weeks); ITT, intent-to-treat; LDL-C, low-density lipoprotein cholesterol; LS, least-
squares; PBO, placebo; PCSK9, proprotein convertase subtilisin/kexin type 9; SE, standard error; W, week.
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(Supplementary Fig. 4). Low titer, treatment-emergent persistent
positive responses in the ADA assay were observed in 4/445 (0.9%)
patients in the 300Q4Wgroup, 3/226 (1.3%) patients in the placebo
group, and 2/110 (1.8%) patients in the 75Q2W group. Five patients
administered alirocumabwere positive in the neutralizing antibody
assay.4. Discussion
In the current study, alirocumab 300Q4W demonstrated sta-
tistically signiﬁcant reductions in LDL-C vs. placebo both in patients
receiving and not receiving concomitant statin at Week 12 (before
possible dose adjustment), Week 24, averaged Weeks 21e24, and
Week 48. In addition, beneﬁcial effects were seen for all secondary
lipid parameters with alirocumab 300Q4W at Week 24, notably
with robust reductions in Lp(a).
Statins are known to upregulate the expression of PCSK9 [9,19];
this phenomenon has been shown to limit the effectiveness of
statins through increased degradation of the LDL receptor [9].
When dosed in combination with a PCSK9 monoclonal antibody,
statins may increase the magnitude of efﬁcacy; however, statins
also increase circulating PCSK9 levels [19,20], which may limit the
durability of effect of a PCSK9 monoclonal antibody over a 4-weekdosing interval through target-mediated clearance [5,6]. This situ-
ation is mitigatedwith higher doses of PCSK9monoclonal antibody.
Our study showed a tendency for a less pronounced least-
squares mean maximum reduction in LDL-C when alirocumab
300Q4W was administered without statin compared with
concomitant statin. That is, both the least-squares mean LDL-C
reduction from baseline to Week 24 (alirocumab 300Q4W:
e52.7%; placebo: e0.3%) and the average LDL-C reduction from
baseline to Weeks 21e24 (alirocumab 300Q4W: e56.9%; placebo:
e1.6%) were numerically smaller in the alirocumab 300Q4W group
not receiving concomitant statin compared with patients receiving
concomitant statin (alirocumab 300Q4W: e58.8%; placebo: e0.1%
and alirocumab 300Q4W: e65.8%; placebo: e0.8%, respectively).
In terms of durability, patients receiving concomitant statin did
tend to see slightly more variation in the level of their LDL-C
reduction over time compared with those who were not
receiving a statin. Furthermore, this variability was more apparent
in those patients who ultimately required dose adjustment atWeek
12. Analysis of the dose adjustment scheme revealed that patients
requiring adjustment at Week 12 had higher mean LDL-C levels at
baseline (no statin: 174.3 mg/dL [4.5 mmol/L]; statin: 123.5 mg/dL
[3.2 mmol/L]) and a more variable response to Q4W dosing
compared with those remaining on alirocumab 300 mg Q4W
(mean baseline LDL-C levels no statin: 143.6 mg/dL [3.7 mmol/L];
Fig. 3. Impact of dosing/frequency adjustment on LDL-C (A and C) and free PCSK9 levels (B and D) in patients in the alirocumab 300 mg Q4W group who were not receiving
statin (A and B) or receiving statin (C and D) (ITT population) e time proﬁle of patientsa. a. Patients who received dose adjustment at Week 12 and had at least one subsequent
injection. Arrows indicate time of dose adjustment. LDL-C, low-density lipoprotein cholesterol; PCSK9, proprotein convertase subtilisin/kexin type 9; Q2W, every 2 weeks; Q4W,
every 4 weeks; SE, standard error.
Table 2
Adverse events and safety laboratory values (safety population).
n (%) Patients not receiving statin Patients receiving statin
Alirocumab Placebo (n ¼ 72) Alirocumab Placebo (n ¼ 157)
75Q2W (n ¼ 37) 300Q4W (n ¼ 146) 75Q2W (n ¼ 78) 300Q4W (n ¼ 312)
TEAEs 31 (83.8) 122 (83.6) 56 (77.8) 55 (70.5) 247 (79.2) 115 (73.2)
Treatment-emergent SAEs 4 (10.8) 19 (13.0) 10 (13.9) 9 (11.5) 34 (10.9) 23 (14.6)
TEAEs leading to discontinuation 3 (8.1) 14 (9.6) 4 (5.6) 4 (5.1) 17 (5.4) 13 (8.3)
TEAEs leading to death 1 (2.7) 1 (0.7) 1 (1.4) 0 0 0
Safety terms of interest
Adjudicated cardiovascular eventsa 0 2 (1.4) 2 (2.8) 1 (1.3) 5 (1.6) 2 (1.3)
General allergic TEAE 9 (24.3) 16 (11.0) 8 (11.1) 8 (10.3) 29 (9.3) 13 (8.3)
General allergic serious (CMQ) 0 1 (0.7) 0 1 (1.3) 1 (0.3) 1 (0.6)
Neurocognitive disorders 1 (2.7) 0 0 2 (2.6) 4 (1.3) 2 (1.3)
Laboratory parameterb
Alanine aminotransferase >3 times ULN 0/37 1/143 (0.7) 1/71 (1.4) 0/75 2/307 (0.7) 1/154 (0.6)
Aspartate aminotransferase >3 times ULN 0/36 1/143 (0.7) 0/71 1/75 (1.3) 4/307 (1.3) 2/154 (1.3)
Creatine kinase >3 times ULN 2/37 (5.4) 5/143 (3.5) 4/71 (5.6) 3/75 (4.0) 10/307 (3.3) 5/154 (3.2)
75Q2W, 75 mg every 2 weeks (with possible dose adjustment to 150 mg every 2 weeks); 300Q4W, 300 mg every 4 weeks (with possible dose adjustment to 150 mg every 2
weeks); CMQ, Custom Medical Dictionary of Regulatory Activities Query; SAE, serious adverse event; TEAE, treatment-emergent adverse event; ULN, upper limit of normal.
a Includes coronary heart disease death, non-fatal myocardial infarction, fatal and non-fatal ischemic stroke, unstable angina requiring hospitalization, congestive heart
failure requiring hospitalization, and ischemia-driven coronary revascularization procedure.
b Regardless of baseline status.
E.M. Roth et al. / Atherosclerosis 254 (2016) 254e262260statin: 110.0 mg/dL [2.8 mmol/L]). After dose adjustment, a more
consistent level of reduction was achieved (highlighted by rela-
tively stable LDL-C levels overWeeks 21e24), indicating that, while300Q4W is effective for the majority of patients studied, irre-
spective of background statin use, the dosing strategy (i.e., Q4W vs.
Q2W) could be tailored to suit the needs of the individual patient.
E.M. Roth et al. / Atherosclerosis 254 (2016) 254e262 261At Week 24, there was a strong and consistent response to
treatment.
A similar proportion of patients receiving placebo and alir-
ocumab with or without statin experienced treatment-emergent
serious adverse events, or discontinued because of adverse
events. The higher rate of injection-site reactions in the alirocumab
300Q4W groups vs. earlier ODYSSEY studies could potentially be
attributed to patients receiving two 1 mL injections at each po-
tential dosage administration Q2W in order to maintain the study
blind (previous studies had one 1 mL injection at each adminis-
tration). Of note, when examined on the basis of the number of
injection-site reactions per double-blind injection, the rate of
injection-site reactions observed in the current study (0.13e0.21
injection-site reactions per injection) is not dramatically different
to the rates seen in other ODYSSEY studies (0.09e0.16 injection-site
reactions per injection) [1,4]. There were no other speciﬁc safety
ﬁndings associated with this dosing regimen. Due to the low
number of patients with positive ADA responses and positive
alirocumab-neutralizing antibody status, no deﬁnite conclusion can
be made regarding the impact of immunogenicity on drug expo-
sure. However, an overlapping of the reduction in LDL-C in anti-
drug/neutralizing antibodies positive and negative patients was
observed.
The results of this study suggest that an alirocumab 300Q4W
regimen may provide an additional treatment option with or
without concomitant statin for patients in need of LDL-C-lowering.
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